Stocktoria
Prelude Therapeutics Inc PRLD
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-09-25
Prelude Therapeutics Inc financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $12.1M | $7.0M | — | — | — |
| R&D expense | $94.3M | $118.0M | $103.4M | $92.9M | $86.8M |
| Operating income | -$104.6M | -$139.7M | -$132.3M | -$123.5M | -$113.7M |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$99.5M | -$127.2M | -$121.8M | -$115.4M | -$111.7M |
| EPS (diluted) | $-1.29 | $-1.68 | $-2.02 | $-2.44 | $-2.43 |
| Operating cash flow | -$56.3M | -$102.9M | -$107.1M | -$83.7M | -$83.5M |
| Free cash flow | -$56.4M | -$103.7M | -$110.6M | -$86.7M | -$85.9M |
| Cash & equivalents | $35.3M | $12.5M | $25.3M | $30.6M | $31.8M |
| Total assets | $141.3M | $175.5M | $277.7M | $220.5M | $305.1M |
| Total liabilities | $72.7M | $44.1M | $40.6M | $25.1M | $19.2M |
| Shareholders' equity | $68.6M | $131.5M | $237.1M | $195.4M | $285.9M |
Source: SEC EDGAR filings · CIK 0001678660 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.